JP2011510024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510024A5 JP2011510024A5 JP2010543345A JP2010543345A JP2011510024A5 JP 2011510024 A5 JP2011510024 A5 JP 2011510024A5 JP 2010543345 A JP2010543345 A JP 2010543345A JP 2010543345 A JP2010543345 A JP 2010543345A JP 2011510024 A5 JP2011510024 A5 JP 2011510024A5
- Authority
- JP
- Japan
- Prior art keywords
- duloxetine
- composition
- layer
- composition according
- particle size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 25
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 17
- 229960002866 duloxetine Drugs 0.000 claims 17
- 239000002245 particle Substances 0.000 claims 11
- 239000012055 enteric layer Substances 0.000 claims 10
- 239000010410 layer Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000011324 bead Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229960000913 crospovidone Drugs 0.000 claims 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000008185 minitablet Substances 0.000 claims 2
- 239000008188 pellet Substances 0.000 claims 2
- 239000004014 plasticizer Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008900332A AU2008900332A0 (en) | 2008-01-25 | Delayed Release Composition and Compound | |
| PCT/AU2009/000028 WO2009092129A1 (en) | 2008-01-25 | 2009-01-09 | Delayed release pharmaceutical composition of duloxetine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011510024A JP2011510024A (ja) | 2011-03-31 |
| JP2011510024A5 true JP2011510024A5 (enExample) | 2012-02-16 |
Family
ID=40900727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543345A Pending JP2011510024A (ja) | 2008-01-25 | 2009-01-09 | デュロキセチンの遅延放出医薬組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110070299A1 (enExample) |
| EP (1) | EP2240173A4 (enExample) |
| JP (1) | JP2011510024A (enExample) |
| CN (1) | CN101939004A (enExample) |
| AU (1) | AU2009206204B2 (enExample) |
| CA (1) | CA2712282A1 (enExample) |
| WO (1) | WO2009092129A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2550033T3 (es) | 2009-12-23 | 2015-11-04 | Ratiopharm Gmbh | Forma de dosificación farmacéutica sólida de ticagrelor |
| CN102908331A (zh) * | 2011-08-01 | 2013-02-06 | 浙江九洲药物科技有限公司 | 一种盐酸度洛西汀肠溶胶囊及其制备方法 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN102579403B (zh) * | 2011-12-26 | 2013-08-21 | 天津市嵩锐医药科技有限公司 | 盐酸度洛西汀药物组合物 |
| US8313774B1 (en) * | 2012-06-26 | 2012-11-20 | Magnifica Inc. | Oral solid composition |
| CN103127023B (zh) * | 2013-03-01 | 2014-08-27 | 河北天成药业股份有限公司 | 一种盐酸度洛西汀肠溶片及其制备方法 |
| GR1008228B (el) * | 2013-04-23 | 2014-06-16 | "Φαρματεν Α.Β.Ε.Ε.", | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου |
| CN103393615B (zh) * | 2013-07-24 | 2015-07-15 | 海南华益泰康药业有限公司 | 一种度洛西汀肠溶小丸及其制备方法 |
| CN104414993A (zh) * | 2013-08-20 | 2015-03-18 | 天津药物研究院 | 一种盐酸度洛西汀肠溶微丸胶囊及其制备方法 |
| JP6815109B2 (ja) * | 2016-06-23 | 2021-01-20 | キョーリンリメディオ株式会社 | デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物 |
| JP6972674B2 (ja) * | 2017-06-06 | 2021-11-24 | ニプロ株式会社 | 経口医薬製剤 |
| JP7046323B2 (ja) * | 2017-09-13 | 2022-04-04 | アリメント工業株式会社 | 多層被覆製剤 |
| JP2020029447A (ja) * | 2018-06-25 | 2020-02-27 | 大原薬品工業株式会社 | 腸溶性高分子及び抗付着剤を含有する顆粒 |
| WO2021126098A1 (en) * | 2019-12-18 | 2021-06-24 | Santa Farma İlaç Sanayi̇ A.Ş. | Gastro-resistant pellet comprising duloxetine |
| CN116617189B (zh) * | 2023-07-26 | 2023-09-26 | 四川尚锐生物医药有限公司 | 一种盐酸度洛西汀缓释胶囊及其制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
| US5362886A (en) * | 1993-10-12 | 1994-11-08 | Eli Lilly And Company | Asymmetric synthesis |
| US5508276A (en) * | 1994-07-18 | 1996-04-16 | Eli Lilly And Company | Duloxetine enteric pellets |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| EP1171417B1 (en) * | 1999-04-09 | 2005-11-09 | Eli Lilly And Company | Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof |
| US6420473B1 (en) * | 2000-02-10 | 2002-07-16 | Bpsi Holdings, Inc. | Acrylic enteric coating compositions |
| US6482440B2 (en) * | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
| UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
| US8003080B2 (en) * | 2002-05-13 | 2011-08-23 | Alexza Pharmaceuticals, Inc. | Delivery of drug amines through an inhalation route |
| JP2006508978A (ja) * | 2002-11-19 | 2006-03-16 | イーライ・リリー・アンド・カンパニー | デュロキセチンを用いる胃腸障害の処置 |
| US7625932B2 (en) * | 2003-10-08 | 2009-12-01 | Eli Lilly And Company | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
| US20050250838A1 (en) * | 2004-05-04 | 2005-11-10 | Challapalli Prasad V | Formulation for sustained delivery |
| AU2005319367B2 (en) * | 2004-12-20 | 2012-05-24 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
| WO2007034503A2 (en) * | 2005-06-20 | 2007-03-29 | Cadila Healthcare Limited | Controlled release dosage formulation of duloxetine |
| WO2007077580A2 (en) | 2006-01-06 | 2007-07-12 | Msn Laboratories Limited | Improved process for pure duloxetine hydrochloride |
| EP1820800A1 (en) * | 2006-02-17 | 2007-08-22 | KRKA, tovarna zdravil, d.d., Novo mesto | Crystalline forms of duloxetine hydrochloride and processes for their preparation |
| US20070292511A1 (en) * | 2006-05-22 | 2007-12-20 | Gershon Kolatkar | Duloxetine hydrochloride delayed release formulations |
| BRPI0720958A2 (pt) * | 2006-12-27 | 2014-03-18 | Lek Pharmaceuticals | Omposição de duloxetina |
-
2009
- 2009-01-09 CN CN2009801017187A patent/CN101939004A/zh active Pending
- 2009-01-09 WO PCT/AU2009/000028 patent/WO2009092129A1/en not_active Ceased
- 2009-01-09 AU AU2009206204A patent/AU2009206204B2/en not_active Ceased
- 2009-01-09 CA CA2712282A patent/CA2712282A1/en not_active Abandoned
- 2009-01-09 US US12/863,882 patent/US20110070299A1/en not_active Abandoned
- 2009-01-09 JP JP2010543345A patent/JP2011510024A/ja active Pending
- 2009-01-09 EP EP20090704911 patent/EP2240173A4/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011510024A5 (enExample) | ||
| JP2013522373A5 (enExample) | ||
| JP2008501025A5 (enExample) | ||
| KR101238156B1 (ko) | 약제학적 제제 | |
| JP2017128614A5 (enExample) | ||
| HRP20161210T4 (hr) | Formulacija obložene tablete i postupak | |
| JP2016516698A5 (enExample) | ||
| JP2014517843A (ja) | 医薬組成物用の圧縮コア | |
| US20080199518A1 (en) | Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution | |
| AU2006228525A1 (en) | Controlled absorption of statins in the intestine | |
| JP2019513800A5 (enExample) | ||
| CA2858522A1 (en) | Methods for treating cardiovascular disorder | |
| CA2905011C (en) | Extended-release topiramate capsules | |
| RS53363B (sr) | Oralne farmaceutske tablete za kontrolisano oslobađanje mesalazina i postupak njihovog dobijanja | |
| JP2013502446A5 (enExample) | ||
| CN104220068A (zh) | 包含奥美沙坦酯和罗苏伐他汀或其盐的药物组合物 | |
| JP2007509891A5 (enExample) | ||
| WO2015154656A1 (zh) | 部分包衣的控释固体制剂 | |
| CN106794149A (zh) | 含ω‑3脂肪酸酯和他汀类的口服给药复合制剂 | |
| WO2016147108A1 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| US20110150942A1 (en) | Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives | |
| JP2014508187A (ja) | 選択的セロトニン再取り込み阻害薬の放出制御医薬組成物 | |
| CA2777856A1 (en) | Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof | |
| US20110020439A1 (en) | Delayed release compositions of duloxetine | |
| EA038861B1 (ru) | Пероральный фармацевтический препарат, покрытый кишечнорастворимой оболочкой , содержащий диметилфумарат |